Kangpu Biopharmaceuticals Ltd.
- Country
- 🇨🇳China
- Ownership
- Holding
- Established
- 2011-01-19
- Employees
- 11
- Market Cap
- -
- Website
- https://www.kangpugroup.com
Clinical Trials
4
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
Phase 1b/2a Study to Evaluate Safety and Efficacy of KPG-818 in SLE
- Conditions
- SLE; Drug
- Interventions
- Drug: KPG-818 mid doseDrug: KPG-818 low doseDrug: KPG-818 high doseDrug: Placebo
- First Posted Date
- 2020-11-24
- Last Posted Date
- 2024-05-23
- Lead Sponsor
- Kangpu Biopharmaceuticals, Ltd.
- Target Recruit Count
- 64
- Registration Number
- NCT04643067
- Locations
- 🇺🇸
Anniston Medical Clinic, Anniston, Alabama, United States
🇺🇸University of Alabama - Birmingham, Birmingham, Alabama, United States
🇺🇸Clinical Research of West Florida, Inc., Clearwater, Florida, United States
Safety, Tolerability and Pharmacokinetics Study of KPG-818 in Hematological Malignancies Subjects
- First Posted Date
- 2020-02-25
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- Kangpu Biopharmaceuticals, Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT04283097
- Locations
- 🇺🇸
UC Davis Comprehensive Cancer Center, Sacramento, California, United States
🇺🇸BRCR Global - USA, Plantation, Florida, United States
🇺🇸Norton Cancer Institute, Louisville, Kentucky, United States
Safety, Tolerability and Pharmacokinetics of KPG-818 in Healthy Subjects
- First Posted Date
- 2019-05-14
- Last Posted Date
- 2020-02-25
- Lead Sponsor
- Kangpu Biopharmaceuticals, Ltd.
- Target Recruit Count
- 40
- Registration Number
- NCT03949426
- Locations
- 🇺🇸
California Clinical Trials Medical Group, Glendale, California, United States
Evaluation of Safety and Efficacy of KPG-121 Plus Enzalutamide, Abiraterone or Apalutamide in CRPC Patients
- Conditions
- Castration-Resistant Prostate Cancer
- First Posted Date
- 2018-06-26
- Last Posted Date
- 2023-07-18
- Lead Sponsor
- Kangpu Biopharmaceuticals, Ltd.
- Target Recruit Count
- 16
- Registration Number
- NCT03569280
- Locations
- 🇺🇸
Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States
🇺🇸North Shore Hematology Oncology Associates DBA NY Cancer and Blood Specialists, Port Jefferson Station, New York, United States
🇺🇸University of Virginia Cancer Center, Charlottesville, Virginia, United States